Clinical trial · Observational
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
Application of the Detection of Circulating Tumor Cell and Circulating Tumor DNA in the Diagnosis of Metastasis in Gastric Cancer
NCT05208372CI-TRIAL-00056177CTC_ctDNAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and hematogenous metastasis of advanced gastric cancer; To explore the influence of the number and type of CTCs and ctDNA on metastasis and prognosis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastasis | — | UNRESOLVED | — |
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTC test | Diagnostic Test | — | UNRESOLVED |
| ctDNA test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Laparotomy group
- description
- Patients who undergo radical laparotomy for gastric cancer.
- interventionNames
- Diagnostic Test: CTC test
- Diagnostic Test: ctDNA test
- label
- Laparoscopy group
- description
- Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
- interventionNames
- Diagnostic Test: CTC test
- Diagnostic Test: ctDNA test
Primary outcomes (3)
- measure
- Quantity of CTCs
- timeFrame
- 1 day
- description
- To count the circulating tumor cells in ascites and blood.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who sign informed consent. 2. Gastric cancer is determined by more than 2 pathologists. 3. Patients with Borrmann III/IV gastric cancer. Exclusion Criteria: 1. Patients who complicate with other malignant tumors. 2. Patients who complicate with other serious heart and lung diseases. 3. Patients who receive preoperative neoadjuvant chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.